An 18-year-old high school graduate has developed an elegant new way to gauge the liver health of astronauts-and it could someday help solve an enduring medical mystery in space.

Each year, the Genes in Space program, founded by Boeing and miniPCR bio and supported by the International Space Station (ISS) U.S. National Laboratory and New England Biolabs, holds an annual student research competition in which students in grades 7 through 12 propose DNA experiments that leverage the unique environment of the ISS.

"Currently there are just so many unknowns about how life responds to the conditions of space, and we'll need to solve those mysteries before we can establish a long-term presence in space," said Genes in Space program lead Katy Martin. "The idea behind the competition is to open the door and invite students to lead the investigations that get us those answers."

Kristoff Misquitta was a high school senior when his idea for a new way to track liver function in astronauts won the national 2020 Genes in Space competition. The concept, launching on Northrop Grumman's 16th Commercial Resupply Services (CRS) mission, will be validated on the ISS and could eventually be used to improve the effectiveness of vital medications during spaceflight.

Misquitta's winning proposal began with a mystery: why don't medications seem to work as well in space as they do on Earth? It is a well-documented phenomenon without a clear explanation-across 79 spaceflight missions, about one in five doses of medication were perceived as not effective.

"When I was doing my research, I was really surprised by a lot of the anecdotes about medicine being taken where it wouldn't work or that the symptoms persisted in a space environment," said Misquitta, now in his first year at the Massachusetts Institute of Technology (MIT).

He guessed that the reason could be differences in the function of astronauts' liver enzymes in space. Spaceflight has been shown to alter the genetic expression of enzymes and other proteins. If these alterations cause changes in the production of liver enzymes, which help the body break down medications, it could mean medicines are processed too slowly or too quickly to be as effective as they are on Earth, Misquitta reasoned.

Working with his high school biology teacher, and later his mentors at MIT and Harvard University, Misquitta devised a way to visualize the level of gene expression from liver enzymes in space. The method pairs a miniature polymerase chain reaction (PCR) machine developed by miniPCR bio with a new fluorescence viewer tool developed by miniPCR bio and Genes in Space, which allows ISS crew members to visualize fluorescent biomolecules on station. The mini-PCR machine amplifies specifically targeted genes, which are then visualized with the viewer, providing an elegant metric: the greater the level of gene expression, the brighter the tubes will glow in the viewer.

If it works, Misquitta's method could prove a simple and cost-effective method to visually gauge the liver health of astronauts, opening the door for further investigations and the development of rapid diagnostic techniques in space. If differences in liver gene expression can reliably be detected, it also could one day help solve the mystery of why some medications are less effective during spaceflight, paving the way for improvements in drug treatments for astronauts.

"Looking at the potential results of this study, I hope the study can reach a much broader scientific audience that can use it as a springboard," Misquitta said. "And hopefully, in the future, it can change the way astronauts take medicine on long-duration missions."

Related Links
ISS US National Laboratory
Genes in Space
Space Medicine Technology and Systems

Thanks for being there; We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Monthly Supporter $5+ Billed Monthly		SpaceDaily Contributor $5 Billed Once credit card or paypal

Tissue engineering in space could treat age-related muscle loss on Earth
Kennedy Space Center FL (SPX) Aug 10, 2021
An investigation headed for the International Space Station (ISS) on Northrop Grumman's upcoming 16th Commercial Resupply Services (CRS) mission could someday enable rapid advancements in treatments for age-related muscle loss. In an experiment funded by the U.S. National Science Foundation (NSF), researchers from the Palo Alto Veterans Institute for Research and Stanford University are leveraging microgravity to develop a tissue-engineered model of sarcopenia, the age-related deterioration of ske ... read more

Read more from original source...